Study Report to DSMC

CTN Study Number	CTNPT 047
Study Title	**Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study**
Investigator	Dr. Jean-Pierre Routy, MD
CTN Services	Project Management, Data Management, Randomization system, Regulatory (Health Canada submissions, Risk Register review), Statistics & Methodology
Study Status	☐ Enrolling ☐ Enrolment suspended (for interim analysis) ☐ Ongoing (Visits ongoing but closed to enrolment) ☒ LPLV completed
Target Enrolment	Total = 60 Participants 40 participants in Intervention arm (Letermovir) 20 participants in Standard of Care arm
Intervention	480mg of letermovir once daily (as 2 x 240mg tablets)
Total Enrolment to date	Total = **43** participants enrolled Completed study = **33** participants Early withdrawal = **10** participants Early withdrawals:
Date of FPFV	07 Oct 2022
Date of LPLV	27 Jan 2025
Description of issues (e.g. study delays, low enrolment; enrolment suspended)	Study terminated based on 06Mar2025 DSMC recommendation to cease further enrolment.

Study Report to DSMC

SAEs (additional information)	None reported to date.
Other Comments	

ATTACHMENTS

Highlight Sheet	☒ YES ☐ NO If No, Reason not attached:
Annual Study Report	☒ YES ☐ NO If No, Reason not attached:
Stats Report	☐ YES ☒ NO If No, Reason not attached: **To be provided by Terry at CTN**